PV Bulletin

UK Position Paper on Microbiome-Based Medicinal Products (MBMPs)

The MHRA has issued a position paper clarifying that microbiome-based medicinal products (MBMPs) fall under the scope of the Human Medicines Regulations 2012, regulating them as biological or advanced therapy medicinal products.

Primary source: Medicines and Healthcare products Regulatory Agency

PV Impact Brief

Urgency: HighConfidence: high

What changed

The MHRA clarified that MBMPs are regulated as biological or advanced therapy medicinal products under the Human Medicines Regulations 2012 and specified requirements for pharmacovigilance systems.

Why it matters

This clarification is crucial for marketing authorization holders (MAHs) and sponsors as it sets expectations for compliance in monitoring unique microbiome-specific safety concerns and enhances the development pathway for innovative therapies.

Action needed

MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.

Relevant for
Regulatory Intelligence LeadSignal Management LeadQPPV
Processes impacted
Signal ManagementCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Position Paper
Policy status
final
Publication date
2026-08-18
Policy change
The MHRA has issued a position paper clarifying that microbiome-based medicinal products (MBMPs) fall under the scope of the Human Medicines Regulations 2012. Depending on their characteristics, they are regulated as biological medicinal products or advanced therapy medicinal products (ATMPs). The paper provides clarity on the UK licensing route to encourage the development of these innovative therapies.

Key changes

Clarification of the regulatory framework (Human Medicines Regulations 2012) for MBMPs; requirements for product characterisation and manufacturing consistency; specific safety assessment expectations including antimicrobial resistance (AMR) risk; and guidance on early engagement with the MHRA Innovation Office.

Affected workflows

Signal ManagementCountry Compliance

Responsible groups

MHRA Innovation OfficeRegulatory AffairsPharmacovigilance Operations

PV impact

MAHs and sponsors of MBMPs must ensure their pharmacovigilance systems are capable of monitoring microbiome-specific safety concerns, such as the potential for antimicrobial resistance transfer. Compliance involves aligning safety monitoring with established biological/ATMP standards while addressing batch-to-batch variability and long-term safety profiles unique to live microbial populations.

View regulator source

Source document details

Exact policy details

Publication Date
18 August 2026
Applies to: All stakeholders involved in the development and licensing of MBMPs in the UK.
Published: 18 August 2026 · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Aug 18, 2026

Full briefing

Practical implication

MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.

The Medicines and Healthcare products Regulatory Agency (MHRA) has clarified the regulatory position for microbiome-based medicinal products (MBMPs) under the Human Medicines Regulations 2012. This guidance is aimed at encouraging the development and licensing of MBMPs in the UK, outlining specific safety assessment expectations, including monitoring for antimicrobial resistance, and ensuring compliance with safety monitoring standards.

What changed: The MHRA clarified that MBMPs are regulated as biological or advanced therapy medicinal products under the Human Medicines Regulations 2012 and specified requirements for pharmacovigilance systems.

Why it matters: This clarification is crucial for marketing authorization holders (MAHs) and sponsors as it sets expectations for compliance in monitoring unique microbiome-specific safety concerns and enhances the development pathway for innovative therapies.

Practical implication: MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#final#policy-change#firecrawl-policy-agent#inspection#Medicines and Healthcare products Regulatory Agency#Position Paper

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward